Literature DB >> 26614941

Update on Survival in Osteosarcoma.

Megan E Anderson1.   

Abstract

Osteosarcoma is the most common primary bone malignancy in children. Treatment has evolved to include systemic chemotherapy and local control surgery. Although survival improved initially in a drastic fashion with this approach, recent decades have seen little to no further gains in this area. Limb salvage surgery evolved with effective chemotherapy and advances in imaging, and continues to improve in the recent era. This article serves as a review of survival in high-grade osteosarcoma: prognostic factors, advances in chemotherapy and surgery, late effects of chemotherapy and surgery in survivors, and future directions.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Late effects; Limb salvage surgery; Osteosarcoma; Prognosis; Survival; Systemic chemotherapy

Mesh:

Year:  2016        PMID: 26614941     DOI: 10.1016/j.ocl.2015.08.022

Source DB:  PubMed          Journal:  Orthop Clin North Am        ISSN: 0030-5898            Impact factor:   2.472


  210 in total

1.  Quantitative Primary Tumor Indocyanine Green Measurements Predict Osteosarcoma Metastatic Lung Burden in a Mouse Model.

Authors:  Mitchell S Fourman; Adel Mahjoub; Jon B Mandell; Shibing Yu; Jessica C Tebbets; Jared A Crasto; Peter E Alexander; Kurt R Weiss
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

2.  Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.

Authors:  Victoria M Wu; Jarrett Mickens; Vuk Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2017-07-28       Impact factor: 9.229

3.  The prognostic significance of circulating serum amyloid A and CXC chemokine ligand 4 in osteosarcoma.

Authors:  Ricardo J Flores; Aaron J Kelly; Yiting Li; Xiang Chen; Colin McGee; Mark Krailo; Donald A Barkauskas; John Hicks; Tsz-Kwong Man
Journal:  Pediatr Blood Cancer       Date:  2017-05-24       Impact factor: 3.167

4.  Diallyl trisulfide regulates cell apoptosis and invasion in human osteosarcoma U2OS cells through regulating PI3K/AKT/GSK3β signaling pathway.

Authors:  Pan He; Zhijun Wang; Bin Sheng; Yongqiang Xu; Siyin Feng; Yan Huang; Fuqiang Gong; Liting Tang; Liming Xie
Journal:  Histol Histopathol       Date:  2020-12-29       Impact factor: 2.303

5.  Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression.

Authors:  Yan Zhou; Rui-hua Zhao; Kuo-fu Tseng; Kun-peng Li; Zhi-gang Lu; Yuan Liu; Kun Han; Zhi-hua Gan; Shu-chen Lin; Hai-yan Hu; Da-liu Min
Journal:  Acta Pharmacol Sin       Date:  2016-02-29       Impact factor: 6.150

6.  Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.

Authors:  Baobiao Zhuo; Yuan Li; Feng Gu; Zhengwei Li; Qingzeng Sun; Yingchun Shi; Yang Shen; Fengfei Zhang; Rong Wang; Xiaodong Wang
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

7.  KIAA1429 promotes osteosarcoma progression by promoting stem cell properties and is regulated by miR-143-3p.

Authors:  Qicai Han; Jie Yang; Hao Yang; Chao Li; Juan Li; Yuan Cao
Journal:  Cell Cycle       Date:  2020-04-14       Impact factor: 4.534

8.  IT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media Communities.

Authors:  Florian Pohlig; Ulrich Lenze; Heinrich M L Muhlhofer; Florian W Lenze; Johannes Schauwecker; Carolin Knebel; Tanja Zimmermann; Peter Herschbach
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 9.  A Comprehensive Review of Aminochalcones.

Authors:  Rimsha Irfan; Shikufa Mousavi; Meshari Alazmi; Rahman Shah Zaib Saleem
Journal:  Molecules       Date:  2020-11-17       Impact factor: 4.411

10.  Capsaicin induces immunogenic cell death in human osteosarcoma cells.

Authors:  Tao Jin; Hongyan Wu; Yanlin Wang; Hao Peng
Journal:  Exp Ther Med       Date:  2016-05-19       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.